![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Amarillo Announces a Clinical Trial in Patients With Bone Marrow Disorders
Amarillo Announces a Clinical Trial in Patients With Bone Marrow Disorders
Amarillo Biosciences will commence a study to test low-dose oral interferon alpha in 40 patients with rare bone marrow proliferative disorders.
The study will be conducted at a major cancer center in Texas with a leading medical authority that specializes in the treatment of these myeloproliferative disorders. Twenty patients, each with either polycythemia vera or primary thrombocythemia, will be given low-dose oral interferon alpha daily as a treatment to relieve the signs and symptoms associated with these disorders.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct